Literature DB >> 19889514

Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome.

Maria I Christodoulou1, Efstathia K Kapsogeorgou, Haralampos M Moutsopoulos.   

Abstract

Sjögren's syndrome (SS) is a chronic autoimmune exocrinopathy associated with variable degree of lymphocytic infiltration of the affected organs (primarily salivary and lacrimal glands) and broad clinical manifestations. Minor salivary gland (MSG) lesions mainly consist of T and B cells, while antigen-presenting cells have been reported in heavy infiltrates. Evidence suggests that the infiltrate composition differs according to lesion severity; however, these differences are not well-defined. To investigate the differential distribution of the major infiltrating mononuclear cell (MNC) types in SS-lesions of variable severity, total-T, CD4(+)-T, CD8(+)-T, Treg, and B cell, macrophage (MPhi), interdigitating (iDC) and follicular dendritic cell (fDC), and natural-killer (NK)-cell incidence (%-total infiltrating MNC) was analyzed in MSG biopsies with mild (n = 11), intermediate (n = 13) or severe (n = 15) lesions. T cells, CD4(+)-T cells and Tregs, B lymphocytes, MPhis and iDCs were significantly different among MSG tissues with mild, intermediate or severe inflammatory lesions, while CD8(+)-T cell, fDC and NK cell incidence was not correlated with lesion severity. T cell, CD4(+)-T cell, T/B cell ratio and iDC incidence was negatively, whereas B cell and MPhi incidence was positively correlated with infiltration grade and biopsy focus score. Tregs predominated in intermediate lesions. Multivariate analysis revealed several associations between the incidence of each infiltrating MNC-type and disease manifestations, implying an involvement of local immune responses in systemic disease features. Our findings support that the distribution of infiltrating MNCs at the SS-lesions varies according to lesion severity and correlates with disease manifestations. The significance of this differential distribution and the underlying aetiopathogenic factors need to be elucidated.

Entities:  

Mesh:

Year:  2009        PMID: 19889514     DOI: 10.1016/j.jaut.2009.10.004

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  126 in total

Review 1.  Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.

Authors:  A Vossenkämper; P M K Lutalo; J Spencer
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

2.  Critical involvement of macrophage infiltration in the development of Sjögren's syndrome-associated dry eye.

Authors:  Delu Zhou; Ying-Ting Chen; Feeling Chen; Marianne Gallup; Trinka Vijmasi; Ahmad F Bahrami; Lisa B Noble; Nico van Rooijen; Nancy A McNamara
Journal:  Am J Pathol       Date:  2012-07-04       Impact factor: 4.307

3.  Biomarkers. Saliva proteomics is a promising tool to study Sjögren syndrome.

Authors:  Athanasios G Tzioufas; Efstathia K Kapsogeorgou
Journal:  Nat Rev Rheumatol       Date:  2015-02-10       Impact factor: 20.543

4.  Single-cell analysis of glandular T cell receptors in Sjögren's syndrome.

Authors:  Michelle L Joachims; Kerry M Leehan; Christina Lawrence; Richard C Pelikan; Jacen S Moore; Zijian Pan; Astrid Rasmussen; Lida Radfar; David M Lewis; Kiely M Grundahl; Jennifer A Kelly; Graham B Wiley; Mikhail Shugay; Dmitriy M Chudakov; Christopher J Lessard; Donald U Stone; R Hal Scofield; Courtney G Montgomery; Kathy L Sivils; Linda F Thompson; A Darise Farris
Journal:  JCI Insight       Date:  2016-06-02

5.  Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome.

Authors:  N Roescher; B M Lodde; J L Vosters; P P Tak; M A Catalan; G G Illei; J A Chiorini
Journal:  Oral Dis       Date:  2011-09-14       Impact factor: 3.511

Review 6.  JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren's Syndrome.

Authors:  Amandine Charras; Pinelopi Arvaniti; Christelle Le Dantec; Marina I Arleevskaya; Kaliopi Zachou; George N Dalekos; Anne Bordon; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

7.  Analysis of IgM antibody production and repertoire in a mouse model of Sjögren's syndrome.

Authors:  Jill M Kramer; Nichol E Holodick; Teresa C Vizconde; Indu Raman; Mei Yan; Quan-Zhen Li; Daniel P Gaile; Thomas L Rothstein
Journal:  J Leukoc Biol       Date:  2015-09-17       Impact factor: 4.962

8.  Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway.

Authors:  N C Kyriakidis; E K Kapsogeorgou; V C Gourzi; O D Konsta; G E Baltatzis; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

9.  Salivary-gland-protective regulatory T-cell dysfunction underlies female-specific sialadenitis in the non-obese diabetic mouse model of Sjögren syndrome.

Authors:  Jennifer Y Barr; Xiaofang Wang; Portia A Kreiger; Scott M Lieberman
Journal:  Immunology       Date:  2018-05-31       Impact factor: 7.397

10.  CXCL13 levels in serum but not in saliva are elevated in Asian Indian patients with primary Sjögren's syndrome.

Authors:  Santosh Kumar Mandal; Pulukool Sandhya; Jayakanthan Kabeerdoss; Janardana Ramya; Gowri Mahasampath; Debashish Danda
Journal:  Rheumatol Int       Date:  2018-03-14       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.